Aspect Partners’s Pelthos Therapeutics PTHS Stock Holding History

Aspect Partners’s Portfolio PTHS Stock Details PTHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16	Closed	-$336	–	765
2026 Q1	$336	Buy	+16	New	+$379	﹤0.01%	677

Other funds holding PTHS

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Aspect Partners's PTHS Position: Q2 2026 in Review

Aspect Partners sold out of Pelthos Therapeutics (PTHS) in Q2 2026, closing a stake of 16 shares — an estimated $336 sold.

Aspect Partners first reported a position in PTHS in Q1 2026 and held it in 1 quarter. The position peaked at $336 in Q1 2026. 2 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

Aspect Partners reported no remaining Pelthos Therapeutics position as of Q2 2026 after selling out during the quarter.
Aspect Partners sold 16 Pelthos Therapeutics shares in Q2 2026, an estimated $336.
Aspect Partners first reported a position in Pelthos Therapeutics in Q1 2026 and held it in 1 quarter.
Aspect Partners's Pelthos Therapeutics position peaked at $336 in Q1 2026.
2 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.